GLOBAL TRASTUZUMAB BIOSIMILARS INSIGHTS, 2024

Trastuzumab, a monoclonal antibody designed to treat HER2-positive breast cancer, has transformed cancer care by specifically targeting the HER2 receptor, which is overexpressed in certain breast cancer cases. As the demand for affordable treatment options continues to grow, trastuzumab biosimilars have become a vital alternative, enhancing access